Eli Lilly | LLY - Sales Revenues

Stock Price
1,044.10
Daily Change
6.95 0.67%
Monthly
0.25%
Yearly
28.83%
Q1 Forecast
1,005.21

Eli Lilly reported $17.6B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 15.78B 360M Sep/2025
Abbott USD 11.46B 90M Dec/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Amgen USD 9.56B 380M Sep/2025
AstraZeneca USD 15.19B 733M Sep/2025
Baxter International USD 2.84B 30M Sep/2025
Biogen USD 2.53B 70M Sep/2025
Bristol-Myers Squibb USD 12.2B 70M Sep/2025
Drreddys Laboratories INR 87.27B 1.82B Dec/2025
Eli Lilly USD 17.6B 2.04B Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
GlaxoSmithKline GBP 8.55B 557M Sep/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
J&J USD 24.6B 610M Dec/2025
Medtronic USD 8.96B 383M Sep/2025
Merck USD 17.28B 1.47B Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Novo Nordisk DKK 76.86B 0 Sep/2025
Perrigo USD 1.04B 16.3M Sep/2025
Pfizer USD 16.7B 2B Sep/2025
Prestige Brands USD 274.1M 24.57M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sanofi EUR 12.2B 3.19B Dec/2025
United Therapeutics USD 799.5M 900K Sep/2025
Zoetis USD 2.4B 60M Sep/2025